Introduction
Congenital adrenal hyperplasia (CAH, OMIM 201910) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disorder of the adrenal cortex characterized by impaired cortisol biosynthesis with or without aldosterone deficiency. The defect in cortisol biosynthesis results in a compensatory increase in corticotrophin and stimulation of the adrenal cortex, leading to androgen excess (Merke and Bornstein 2005) . CAH manifests a broad spectrum of phenotypes and is classified according to clinical severity: the classic or severe form occurs in approximately one case per 15,000 live births worldwide (Merke and Bornstein 2005) , while a more common mild or nonclassic (NC) form has a prevalence of one in 1,000 in Caucasians (Speiser et al. 1985) .
The CYP21A2 (OMIM 201910) gene encoding 21-hydroxylase is mapped at the central region of the human major histocompatibility complex on chromosome 6, and is in tandem with three neighboring genes (RP1, C4 and TNXB) from the telomeric to centromeric ends to constitute a genetic module termed RCCX (RP-C4-CYP21-TNX). RP1 (synonym for STK19) encodes a serine/threonine nuclear protein kinase, C4 encodes for the immune effector protein complement component, and tenascin (TNX) is a member of the extracellular matrix protein family. With the exception of C4, each of the other functional genes (RP1, CYP21A2 and TNXB) has a corresponding highly homologous pseudogene [RP2 (synonym for STK19P), CYP21A1P and TNXA]. Due to the highly homologous sequences between functional and pseudogenes, the RCCX modules are characterized by modular duplication or deletion events in which each duplicated or deleted module usually covers a CYP21A1P-TNXA-RP2-C4 unit. Although bimodular RCCX is the most common haplotype, great variation of RCCX length has been observed to generate misalignment between homologous genes during meiosis, leading to unequal crossovers (Blanchong et al. 2000) . Consequently, copy number variation (CNV) of C4, CYP21, and TNX is widely found in humans and this complexity has challenged the genetic analysis of relevant human conditions.
One of the major clinical aspects of the genetics of RCCX is C4 CNV. C4 is an important effector protein that plays a crucial role in the classical and the mannose-binding lectin activation pathways of the immune system (Walport 2001a, b; Yu et al. 2003) . In addition to two isotopes, the human C4 gene can be either 21 kb (C4 long, C4L) or 14.6 kb (C4 short, C4S) in length, depending on the integration of the endogenous retrovirus HERV-K (C4) into the ninth intron. While complete C4 deficiency is extremely rare, susceptibility to autoimmune diseases such as systemic lupus erythematosus has been associated with lower C4 copy number and lower serum C4 protein levels (Yang et al. 2007 ).
The present study is among our series of comprehensive genetic investigations of RCCX in a large cohort of patients with CAH (Chen et al. 2009 (Chen et al. , 2012 Finkielstain et al. 2011) . In CAH, the majority of CYP21A2 mutations originate from the CYP21A1P pseudogene and are transferred by gene conversion during meiosis (Koppens et al. 2002) . This high frequency of RCCX crossover events led us to hypothesize that CAH patients may have C4 CNV associated with specific CYP21A2 genotypes that may modulate autoimmune disease risk.
The aim of our study was to extend the genetic analysis of the RCCX module to evaluate C4 CNV in our large CAH cohort. We determined a copy number of total C4, C4L and C4S and evaluated C4 CNV in relation to CYP21A2 genotype, expected population C4 CNV (Saxena et al. 2009 ), autoimmune disease, and serum C4 protein levels.
Methods

Patients
We evaluated 127 unrelated patients with CAH due to 21-OHD (100 classic, 27 NC; 63 males, 64 females; mean age ± SD: 18.5 ± 13.1 years; Fig. 1 ), a subgroup of our previously reported cohort enrolled in a Natural History Study at the NIH Clinical Center in Bethesda, MD, USA (Clinical Trial No. NCT00250159) (Finkielstain et al. 2011) . Only patients with complete genetic data, including Southern blot, were included. Autoimmune disease status was determined per clinical history and medical records. The study was approved by The Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional Review Board. Informed consent and assent for minors C8 years old were obtained.
Genotyping of the RCCX module
Defective CYP21A2 alleles of each patient were confirmed in a comprehensive approach, including sequencing, Southern blot, multiplex ligation-dependent probe amplification (MLPA), and other PCR-based methods (Finkielstain et al. 2011) . Consistent nomenclature was utilized to define mutations of the CYP21A2 gene (Finkielstain et al. 2011) .
Per established protocol (Chung et al. 2005) , TaqI and PshAI Southern blot was performed to characterize the RCCX modules (Finkielstain et al. 2011) . The probe A used in the TaqI Southern blots provided genotyping of four possible combinations between the RP (RP1 and RP2) and C4 (C4L and C4S) genes. The PshAI digestion was employed to confirm copy number ratio between RP1 and RP2 genes, which confirmed the total number of RCCX modules, hence C4 gene dosages seen in TaqI digestion.
C4 serum protein concentrations
Serum protein concentrations of C4 were determined by a Vista analyzer (NIH Clinical Center Laboratory, Bethesda, MD, USA). Gene copy numbers of total C4, C4L, and C4S were compared among groups using Chi-square test, Fisher's exact test, as appropriate. Group comparisons of C4 serum concentrations were carried out using the independent t test or one-way analysis of variance, as appropriate. Average values were expressed as mean ± SD. A two-tailed p value of\0.05 was considered significant. Analyses were performed using SPSS statistical software V19.0.0 (SPSS Inc, Chicago, IL, USA).
Results
Great RCCX length variation was observed and the CNV of each gene corresponded to the number of RCCX modules (Fig. 2a, b) . Overall, only 39 % of our CAH population had the most commonly reported four copies of C4, as compared to 61 % of population estimates (Saxena et al. 2009 ). C4 copy number was significantly higher in the nonclassic than the classic group (5.30 ± 0.82 vs. 3.57 ± 0.96; p = 3.52 9 10 -14 ) (Fig. 2c ). Correspondingly, the serum level of total C4 was greater in NC than classic patients (33.0 ± 6.3 vs. 21.2 ± 6.6; p = 4.14 9 10 -5
). Similar numbers of CAH patients had extremely low (9.4 % with 2) and high (14.2 % with 6-7) copies of C4. When compared with a previously published group of healthy European Americans (Saxena et al. 2009 ), our CAH patients had a different C4 copy number distribution (p = 5.24 910 -12 ), which was greatest for C4S (p = 7.96 9 10 -12 ). The copy numbers of RP1-C4L, RP1-C4S, RP2-C4L and RP2-C4S in our CAH population were 247, Fig. 2 Copy number variation (CNV) of RCCX (RP-C4-CYP21-TNX) modules and C4 genes. a Schematic representation of four types of RCCX haplotypes resulting from modular duplication or deletion events at the central region of the human major histocompatibility complex (MHC) on chromosome 6. b CNV of the RCCX constituting genes was found by Southern blotting with TaqI and PshAI restriction fragment length polymorphism (RFLP). The control shows equal intensity of RP1 and RP2, indicating four copies of C4: one is short and three are long. Patient 1 is homozygous for a monomodular RCCX with a C4S gene and lacks RP2, CYP21A1P and TNXA. Similarly, Patient 2 is homozygous for a monomodular RCCX with a C4L gene. Patient 3 has four copies of C4, which are all long. Patient 4 has six copies of C4: four are short and the other two are long because the 5.4 kb RP2-C4S TaqI band is twice as intense as the 7.0 kb RP1-C4L TaqI band (confirmed by a PshAI Southern blot), and the same intensity ratio of CYP21A1P:CYP21A2 and TNXA:TNXB. c Phenotypic variation was observed for total C4 copy number 7, 110, and 136, respectively. There was a significant association between RP and long or short C4 genes (p = 1.31 9 10 -38 ) regarding relative location. This suggests that the RP1 gene is overwhelmingly in tandem with the C4L gene in RCCX modules. Three of the seven RP1-C4S alleles were determined to be a monomodular RCCX module with a C4S gene (mono-S). Although we were not able to determine the phases of RCCX modules where the remaining four RP1-C4S alleles were located, the allele frequency of mono-S in our CAH patients was significantly lower than published norms (p = 1.08 9 10 -4 ). None of our NC CAH patients had the mono-S haplotype, a risk factor for autoimmune disease; 1.5 % of the classic CAH patients had this haplotype. V281L, the most common nonclassic CYP21A2 mutation, was associated with high C4 copy number (Table 1 ). In addition, higher V281L mutation copy number was associated with increased copies of C4 (Table 1) . No association was found between other less frequent nonclassic CYP21A2 mutations and C4 copy number.
C4 copy number was also significantly different based on the copy number of chimera genes at the RCCX locus (Table 1) ; having a chimera gene at the RCCX locus was associated with a decrease in C4 copy number. The overall distribution difference of C4 copy number was significant when deletion copy number varied (Table 1 ). In particular, 75 % (9 out of 12) of patients who carried two copies of C4 had two copies of chimera genes, accounting for approximately two-thirds of the patients who carried two chimera genes.
In our cohort of 127 CAH patients, four had history of autoimmune disease: two with Hashimoto thyroiditis, one with inflammatory bowel disease, and one with seronegative juvenile rheumatoid arthritis. No association was found between history of autoimmunity and C4 CNV or C4 serum levels.
Discussion
In this study, we report a comprehensive investigation of the complement component 4 gene in a large cohort of North American patients with CAH due to 21-OHD. In genetic studies of the RCCX module, the C4, CYP21A2, and TNXB genes have been studied extensively in autoimmune disease, CAH, and connective tissue disorders, respectively. Extending genetic analysis from a causative single gene perspective to the whole RCCX module in relation to phenotype is of great importance, as exemplified by cases of TNX-deficiency found in CAH patients (Burch et al. 1997; Chen et al. 2009 ). High frequency of CNV has been found at the CYP21A2 locus (Kleinle et al. 2009; Koppens et al. 2002; Parajes et al. 2008; Sinnott et al. 1991; Wedell et al. 1994 ). In the current study, we found that CAH patients have greater C4 CNV, with mutationspecific associations that may be protective for autoimmune disease.
Our patients with CAH demonstrated a significantly different distribution of C4 copy number than expected (Saxena et al. 2009; Yang et al. 2003) , with an increase in extremely low and high C4 copy number. Interestingly, the approximate 20 % decrease in the expected four copies of C4 in our cohort was almost equally distributed between the groups with either 2 or C6 C4 copies. This suggests that unequal crossover events in the population of defective CYP21A2 carriers resulted in an increase of monomodular and longer (trimodular or quadrimodular) RCCX haplotypes, and that these haplotypes were transmitted to and concentrated in the CAH population. Therefore, having CAH appears to increase the probability of having either very low or very high C4 copy number.
Nonclassic CAH is one among the most common autosomal recessive diseases, with Ashkenazi Jews having the highest prevalence (New 2006) . We report the novel a Gene Copy Index (GCI) indicates that mean ± SD of C4 copy number within a selected population (Yang et al. 2007) finding of an association between the V281L mutation, the most frequent CYP21A2 mutation found in NC CAH patients (Finkielstain et al. 2011; New 2006) , and an increase in C4 copy number, indicating that the V281L mutation may be much more frequent in longer RCCX modules at a haplotype level. Since higher C4 copies are protective against autoimmune disease, our finding leads to an intriguing hypothesis that carrier status for V281L may present an evolutionary advantage. Under the alignment model proposed by Blanchong et al. (2000) to explain possible pairings of heterozygous RCCX length variants during meiosis, the CYP21A2 gene carrying a V281L mutation may discourage alignment to the homologous sequence on the paired chromosome. Consequently, the V281L mutation is enriched in longer RCCX modules with higher C4 copy number. Furthermore, higher C4S copy number and greater serum level of total C4 in the NC patients support the role of C4S in increasing C4 protein concentration (Saxena et al. 2009 ). The RCCX module is characterized by modular duplication or deletion events. In particular, large gene deletions result in chimera genes at the centromeric tail of the RCCX module, which account for approximately 30 % of CYP21A2 mutations (Finkielstain et al. 2011; Stikkelbroeck et al. 2003) . These chimera genes are mostly present in a form of CYP21A1P/CYP21A2 (Chen et al. 2012 ), but also TNXA/ TNXB in subset of patients in which the functional CYP21A2 gene is completely deleted and the deletion extends into the TNXB gene (Burch et al. 1997; Chen et al. 2009 ). As expected, we found that having a chimera gene at the RCCX locus was associated with a decrease in total C4 copy number, but this was not associated with autoimmune disease.
Our findings support prior studies of C4 in classic CAH patients; the low frequency of mono-S allele was reported in a relatively small cohort of 22 classic CAH patients (Blanchong et al. 2000) and in 46 unrelated Brazilian classic CAH patients (Guerra-Junior et al. 2008) . Previous studies suggest that lower frequency of mono-S might reduce autoimmune disease risk (Blanchong et al. 2000; Saxena et al. 2009 ). Similarly, the reduced frequency of mono-S in our CAH cohort may explain our low incidence of autoimmune disorders, however, the young age distribution of the patients may be a confounder. Further studies of CAH patients and their relatives who are carriers of CYP21A2 mutations would expand our understanding of the relationship between specific CAH mutations, C4 copy number and autoimmune disease.
The human C4 locus has been identified as a functional CNV hotspot (Fu et al. 2010) . The genome architecture at these CNV loci has a potential role in stirring up mutational events (Fu et al. 2010) . Harboring a highly homologous sequence, the RCCX module is inherently prone to gene duplication or deletion events by virtue of specific characteristics of the local DNA sequence environment (Cooper et al. 2011 ). The involvement of multiple genes in these events results in concurrent CNVs across the surrounding genes. Consequently, the overall clinical phenotypes of a patient go beyond the simple pattern of ''single gene disorder'' when the causative gene is located in a functional CNV hotspot. Our data provide insight into the genetics of CNV hotspots, the effect on multiple neighboring genes, and the ultimate impact on human disease.
